CD274 and neoplasm: Currently, there are two major limitations in evaluating potential biomarkers for cancer immunotherapy: first, although many promising markers have been identified, such as PD‐L1 expression, tumor mutational load (TMB), and immune cell infiltration, the predictive power of these markers is not always consistent and exhibits variability in different types of cancer.